What's Happening?
Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, has announced that two abstracts detailing real-world clinical outcomes for its drug Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted
for presentation at the 68th American Society of Hematology (ASH) Annual Meeting. The meeting is scheduled to take place in New Orleans, USA, from December 12–15, 2026. These abstracts are based on two independent multicenter retrospective studies conducted in Spain and Italy, involving a total of 82 heavily pretreated RRMM patients. The studies aim to reinforce the clinical utility and manageable safety profile of Pepaxti when used in combination with dexamethasone in real-world European clinical practice. This includes its application in patients who have previously received T-cell-redirecting immunotherapies, such as anti-BCMA and anti-GPRC5D agents, and as a bridging therapy between immunotherapies.
Why It's Important?
The presentation of real-world evidence for Pepaxti at a major U.S. medical conference like ASH is significant for several reasons. It provides further validation of the drug's effectiveness and safety profile in a challenging patient population, particularly those who have exhausted other treatment options or are relapsing after advanced immunotherapies. As the treatment landscape for multiple myeloma continues to evolve with the earlier adoption of novel immunotherapies, physicians are increasingly encountering patients who relapse after treatments like anti-BCMA or anti-GPRC5D. The data from these European studies suggest that Pepaxti offers a clinically meaningful and manageable treatment option in these complex scenarios, potentially extending the lives of patients and improving their quality of life. This evidence could influence treatment guidelines and physician prescribing patterns in the U.S., offering a new avenue for patients with heavily pretreated RRMM.
What's Next?
The upcoming presentation at the ASH 2026 Annual Meeting will bring these real-world findings to a broader audience of hematology specialists, researchers, and pharmaceutical stakeholders. The detailed results, including overall response rates, duration of response, progression-free survival, and overall survival, along with safety profiles, will be critically evaluated. Positive reception and discussion at the conference could lead to increased interest in Pepaxti as a viable treatment option for heavily pretreated RRMM patients in the U.S. and globally. Furthermore, the data on Pepaxti's use post-immunotherapy and as a bridging therapy could inform future clinical trial designs and treatment strategies, potentially leading to its integration into more comprehensive treatment algorithms for multiple myeloma.
Beyond the Headlines
The focus on real-world evidence (RWE) in these studies highlights a growing trend in pharmaceutical research and regulatory evaluation. RWE, derived from routine clinical practice rather than highly controlled clinical trials, offers valuable insights into how drugs perform in diverse patient populations and under varied clinical conditions. This approach is becoming increasingly crucial for understanding the long-term effectiveness and safety of therapies, especially for complex diseases like multiple myeloma where patients often have multiple comorbidities and prior treatments. The successful application of Pepaxti in heavily pretreated patients, including those who have received advanced immunotherapies, underscores the ongoing need for diverse therapeutic options to address treatment resistance and improve outcomes in this challenging cancer. This also points to the evolving role of RWE in shaping medical practice and drug development strategies.
